STI571: a paradigm of new agents for cancer therapeutics.
暂无分享,去创建一个
B. Druker | M. Heinrich | M. Mauro | Brian J Druker | M. O'Dwyer | Michael O'Dwyer | Michael C Heinrich | Michael J Mauro
[1] J. Griffin,et al. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.
[2] Susan M. Watanabe,et al. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.
[3] C. Heldin,et al. Involvement of platelet-derived growth factor in disease: development of specific antagonists. , 2001, Advances in cancer research.
[4] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[5] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.
[6] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[7] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[8] K. Kolibaba,et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. , 2000, Blood.
[9] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[10] R. Davis,et al. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties , 1985, Molecular and cellular biology.
[11] A. Levitzki,et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors , 1988, Science.
[12] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[13] A. Ho,et al. Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors , 1999, Cancer Chemotherapy and Pharmacology.
[14] B. Druker,et al. Chronic myeloid leukemia: current treatment options. , 2001, Blood.
[15] M. Carroll,et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.
[16] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[17] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[18] N. Rosenberg,et al. The viral and cellular forms of the Abelson (abl) oncogene. , 1988, Advances in virus research.
[19] J. Spivak,et al. Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497 , 2000 .
[20] M. Greaves,et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. , 1996, Oncogene.
[21] S. Hirota,et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.
[22] B. Zehnbauer,et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.
[23] J. Hasford,et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.
[24] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[25] G. Jenster,et al. Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.
[26] E. Buchdunger,et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.
[27] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[28] R. Salgia,et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.
[29] P. Black,et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.
[30] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[31] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[32] K. Kolibaba,et al. Protein tyrosine kinases and cancer. , 1997, Biochimica et biophysica acta.
[33] G. Daley,et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.
[34] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[35] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[36] Z. Estrov,et al. Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.
[37] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[38] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[39] N. Rosenberg,et al. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Zucchetti,et al. Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .
[41] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[42] D. Tenen,et al. Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.
[43] Z. Estrov,et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] M. Heinrich,et al. STI 571 inhibits the kinase activity of wild type and juxtamembrane C-kit mutants but not the exon 17 D816V mutation associated with mastocytosis , 2000 .
[45] M. Tomasson,et al. TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor , 1999 .
[46] J. Stephenson,et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.
[47] S. Honsawek,et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] Todd R. Golub,et al. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.
[49] S. Hirota,et al. Biological and clinical review of stromal tumors in the gastrointestinal tract. , 2000, Histology and histopathology.
[50] T. Hunter,et al. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.
[51] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[52] J. Rowley. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.
[53] E. Canaani,et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.
[54] J. Melo,et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.
[55] J. Fletcher,et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.